Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Zanubrutinib, Lenalidomide, Rituximab, Temozolomide and Methotrexate (RLZT ± MTX) As First-Line Treatment for Newly Diagnosed PCNSL: A Prospective, Open-Label, Multicenter Clinical Trial

Rong Fu, Jia Song, Hui Liu, Zongjiu Jiao, Da Gao, Kai Ding, Jie Zhuo, Huijuan Jiang, Shan Gao, Yue Ren, Lijuan Li, Yihao Wang

Blood (2024) 144 (Supplement 1): 7786.

https://doi.org/10.1182/blood-2024-209056

Published: 2024

Journal Articles

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Jennifer L. Crombie, Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Celeste Carey, Aaron Zou, Samantha Normilus, Josie Montegaard, Jacob D. Soumerai, Shruti Bhandari, Jon E. Arnason, Alvaro J Alencar, Austin I. Kim, Erin M. Parry, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 4628.

https://doi.org/10.1182/blood-2024-199234

Published: 2024

Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2024) 144 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2024-206556

Published: 2024

Journal Articles

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Daniel Sungchul Choi, Yue Ren, Svitlana Tyekucheva, Stacey M. Fernandes, Mariia Mikhaleva, Kiyomi Mashima, Rayan Fardoun, Samantha J. Shupe, Stephen Martindale, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn

Blood (2024) 144 (Supplement 1): 587.

https://doi.org/10.1182/blood-2024-208951

Published: 2024

Journal Articles

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Inhye E. Ahn, Yue Ren, David C. Fisher, Austin I. Kim, Nancy E. Kaddis, Jon E. Arnason, John P. Winters, III, Sobana Balasubramanian, Heather A. Walker, Victoria Patterson, Stacey M. Fernandes, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2024-201668

Published: 2024

Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2022) 140 (Supplement 1): 837–838.

https://doi.org/10.1182/blood-2022-168003

Published: 2022

Journal Articles

Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease

Mateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, Daisy Alapat, Adam Bagg, Joshua D Brandstadter, Mary Jo Lechowicz, Hongzhe Lee, Gordan Srkalovic, Megan S. Lim, Frits van Rhee, David C Fajgenbaum

Blood (2022) 140 (Supplement 1): 6520–6521.

https://doi.org/10.1182/blood-2022-170102

Published: 2022

Journal Articles

Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter's Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia

Abi Vijenthira, Aswin Sekar, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Yue Ren, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 9868–9870.

https://doi.org/10.1182/blood-2022-163273

Published: 2022

Journal Articles

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Blood (2019) 134 (Supplement_1): 1540.

https://doi.org/10.1182/blood-2019-131367

Published: 2019

Journal Articles

Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes

Sheila K Pierson, MS, Aaron James Stonestrom, MDPhD, Jason R Ruth, PhD, Dustin Shilling, PhD, Hongzhe Li, PhD, Yue Ren, MS, Katie Stone, BS, Frits van Rhee, MD PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2017) 130 (Supplement 1): 3592.

https://doi.org/10.1182/blood.V130.Suppl_1.3592.3592

Published: 2017

Journal Articles

Preliminary Study on the Abnormal DNA Methylation in T Cells from the Patients with Immune Related Pancytopenia

Zonghong Shao, MD, Yue Ren, Rong Fu, PhD

Blood (2014) 124 (21): 5156.

https://doi.org/10.1182/blood.V124.21.5156.5156

Published: 2014

Journal Articles

Hypomethylation and Overexpression of CD70 in CD4 + T Cells of the Patients with Immuno-Related Pancytopenia

Zonghong Shao, MD, Yue Ren, Rong Fu, PhD

Blood (2014) 124 (21): 5157.

https://doi.org/10.1182/blood.V124.21.5157.5157

Published: 2014

Journal Articles

Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia

Artur Slupianek, Yashodhara Dasgupta, Shu-yue Ren, Ewa Gurdek, Milene Donlin, Margaret Nieborowska-Skorska, Fabrice Fleury, Tomasz Skorski

Blood (2011) 118 (4): 1062–1068.

https://doi.org/10.1182/blood-2010-09-307256

Published: 2011

Includes: Supplemental data

Journal Articles

Targeting Phosphotyrosine-315 In RAD51 Recombinase to Prevent BCR-ABL1 - Mediated Unfaithful Homeologous Recombination Repair.

Artur Slupianek, PhD, Yashodhara Dasgupta, Shu-yue Ren, PhD, Kimberly Cramer, Tomasz Skorski, MD, PhD

Blood (2010) 116 (21): 1190.

https://doi.org/10.1182/blood.V116.21.1190.1190

Published: 2010

NARROW

Zanubrutinib, Lenalidomide, Rituximab, Temozolomide and Methotrexate (RLZT ± MTX) As First-Line Treatment for Newly Diagnosed PCNSL: A Prospective, Open-Label, Multicenter Clinical Trial

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease

Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter's Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes

Preliminary Study on the Abnormal DNA Methylation in T Cells from the Patients with Immune Related Pancytopenia

Hypomethylation and Overexpression of CD70 in CD4 + T Cells of the Patients with Immuno-Related Pancytopenia

Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia

Targeting Phosphotyrosine-315 In RAD51 Recombinase to Prevent BCR-ABL1 - Mediated Unfaithful Homeologous Recombination Repair.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only